SCHEMBL4701003

SCHEMBL4701003

S=C=NCCc1cccc(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MIF P14174 9/20 0.67
TRPA1 O75762 1/20 0.63
CYP2E1 P05181 1/20 0.63
CYP2A6 P11509 1/20 0.63
HIF1A Q16665 1/20 0.63
CYP2A13 Q16696 1/20 0.63
EPAS1 Q99814 1/20 0.63
HTR3E A5X5Y0 1/20 0.54
HTR3B O95264 1/20 0.54
HTR3A P46098 1/20 0.54
HTR3D Q70Z44 1/20 0.54
HTR3C Q8WXA8 1/20 0.54
TAAR1 Q96RJ0 3/20 0.53
C3AR1 Q16581 1/20 0.53
NAAA Q02083 3/20 0.47
PNMT P11086 1/20 0.47
AOC3 Q16853 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29542006 0.81 HTR3E (0.54) MIFHTR3EHTR3BHTR3AHTR3D
SCHEMBL1851734 0.81 HTR3E (0.54) MIFHTR3EHTR3BHTR3AHTR3D
SCHEMBL2107951 0.81 MIF (0.65) MIFTRPA1HTR3EHTR3BHTR3A
SCHEMBL2945386 0.80 MIF (0.65) MIFTRPA1CYP2E1CYP2A6HIF1A
SCHEMBL1457483 0.79 MIF (1.00) MIFTRPA1CYP2E1CYP2A6HIF1A
Phenethylisothiocyanate SCHEMBL27616786 0.78 MIF (1.00) MIFTRPA1CYP2E1CYP2A6HIF1A
Phenethylisothiocyanate SCHEMBL156960 0.78 MIF (1.00) MIFTRPA1CYP2E1CYP2A6HIF1A
SCHEMBL12050856 0.77 TAAR1 (0.74) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL5543807 0.77 TAAR1 (0.57) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL332410 0.75 MIF (0.79) MIFTRPA1CYP2E1CYP2A6HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1330451-B1 SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS ORTHO MCNEIL PHARM INC (US) 2008-01-23 EP disclosed
US-6653478-B2 Psychological disorders; hypotensive agents ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-25 US disclosed
EP-1330451-A2 SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS Ortho-McNeil Pharmaceutical, Inc. (US) 2003-07-30 EP disclosed
US-20030073842-A1 Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-04-17 US disclosed
WO-2002055514-A2 SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS ORTHO MCNEIL PHARM INC (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073842-A1 Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators AVPR2, NPY1R, AVPR1B MIF 1570/4885TRPA1 2795/4885CYP2E1 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.